TECX (Tectonic Therapeutic) Moat Score: 3/10 (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TECX Tectonic Therapeutic Inc TECX
14 GF Score
Price $33.98
! 3 Warning Signs
View Full Analysis

What is Tectonic Therapeutic Moat Score?

Tectonic Therapeutic TECX -7.84% 14 Moat Score is 3 as of Aug. 13, 2026. GuruFocus rates TECX with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,388 Biotechnology companies, Tectonic Therapeutic ranks better than 75.5% on this metric.

Tectonic Therapeutic has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Tectonic Therapeutic has No Moat: Tectonic Therapeutic lacks significant market leadership or customer switching costs. While it may have some intellectual property, it does not possess strong brand strength or durable cost advantages. Its competitive position is weak and transient.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Tectonic Therapeutic might have No Moat - Very weak/transient advantages.

Tectonic Therapeutic  (NAS:TECX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Tectonic Therapeutic Moat Score Related Terms

TECX vs ZVRA, SPRY, RLMD: Moat Score Comparison

For the Biotechnology subindustry, Tectonic Therapeutic's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tectonic Therapeutic Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tectonic Therapeutic's Moat Score distribution charts can be found below:

* The bar in red indicates where Tectonic Therapeutic's Moat Score falls into.


TECX
14GF Score
Tectonic Therapeutic Inc TECX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Tectonic Therapeutic (TECX) has a Moat Score of 3 as of Aug. 13, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Tectonic Therapeutic ranks #340 out of 1388 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Tectonic Therapeutic's Moat Score too high?
Tectonic Therapeutic's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Tectonic Therapeutic's value of 3 is 50% above this industry median. Based on the distribution chart, Tectonic Therapeutic ranks #340 out of 1388 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tectonic Therapeutic has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Tectonic Therapeutic's Moat Score compare to ZVRA and SPRY?
According to the Biotechnology industry distribution chart, Tectonic Therapeutic ranks #340 out of 1388 companies for Moat Score. This places Tectonic Therapeutic in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Tectonic Therapeutic's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,388 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tectonic Therapeutic's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tectonic Therapeutic's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tectonic Therapeutic stock overvalued right now?
Tectonic Therapeutic (TECX) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Tectonic Therapeutic's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Tectonic Therapeutic (TECX), the current Moat Score is 3 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tectonic Therapeutic Business Description

Address 490 Arsenal Way, Suite 210, Watertown, MA, USA, 02472
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
14GF Score

Get the complete analysis for TECX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.98
Price